Anti-LILRB4/ILT3/CD85k Antibody is a potent monoclonal antibody targeting the inhibitory receptor LILRB4, acting by blocking the binding of LILRB4 to its ligands such as APOE. The compound is an essential tool for investigating myeloid immune checkpoints, immune escape in acute myeloid leukemia (AML), and mechanisms of immune tolerance induction, aiming to restore the anti-tumor activity of effector T cells by lifting LILRB4-mediated signaling inhibition.
Target:
Others
T9901A-1430
* VAT and and shipping costs not included. Errors and price changes excepted
